Hims & Hers Health (NYSE:HIMS) Announces Quarterly Earnings Results, Beats Expectations By $0.26 EPS

Hims & Hers Health (NYSE:HIMS) announced its quarterly earnings data on Monday. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26, Briefing.com reports. The firm had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The business’s quarterly revenue was up 77.1% compared to the same quarter last year. During the same period last year, the company posted ($0.04) EPS. Hims & Hers Health updated its Q4 2024 guidance to EPS and its FY 2024 guidance to EPS.

Hims & Hers Health Trading Up 3.6 %

NYSE HIMS traded up $0.74 during trading hours on Tuesday, reaching $21.50. 32,290,593 shares of the company’s stock were exchanged, compared to its average volume of 8,437,679. The firm has a fifty day moving average of $18.10 and a 200-day moving average of $18.19. Hims & Hers Health has a one year low of $6.23 and a one year high of $25.74. The stock has a market cap of $4.62 billion, a PE ratio of 271.03 and a beta of 1.06.

Wall Street Analyst Weigh In

HIMS has been the topic of several research reports. Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Deutsche Bank Aktiengesellschaft lifted their price objective on Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research report on Wednesday, August 7th. Needham & Company LLC began coverage on Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price for the company. Truist Financial increased their price objective on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research report on Thursday, July 18th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $21.00 target price (up previously from $18.00) on shares of Hims & Hers Health in a research report on Tuesday. Eight research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $20.71.

Insiders Place Their Bets

In other news, insider Soleil Boughton sold 2,345 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $14.65, for a total value of $34,354.25. Following the completion of the sale, the insider now directly owns 159,796 shares in the company, valued at approximately $2,341,011.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, insider Soleil Boughton sold 2,345 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $14.65, for a total value of $34,354.25. Following the transaction, the insider now owns 159,796 shares of the company’s stock, valued at approximately $2,341,011.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Michael Chi sold 7,500 shares of Hims & Hers Health stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $22.20, for a total transaction of $166,500.00. Following the sale, the insider now owns 193,980 shares of the company’s stock, valued at approximately $4,306,356. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 650,659 shares of company stock valued at $11,712,198. 17.71% of the stock is currently owned by corporate insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.